Shengxiang Bio pointed out in a supplementary
Posted: Wed Feb 12, 2025 10:32 am
The company has been engaged in the research, development and production of genetically recombinant products and biological products. Its main products are human growth hormone (short-acting powder injection, short-acting water injection). It also has an integrated production workshop and new drug research and development center that meets national GMP standards and masters core process technologies. The company independently produces all products from raw materials to final products, covering the front and end of the industrial chain.
This acquisition has a certain premium. As of the valuation base date of May 31, 2024, the book value of all shareholders' equity of Zhongshan Haiji was RMB 259 million, the valuation was RMB 810 million, the appreciation was RMB 551 million, and the appreciation rate was 212.64%.
On the evening of January 12, announcement that it had updated the financial data of Zhongshan Haiji.
The company also pointed out the risks. Since the equity job seekers data acquisition is a merger of companies under different control, after the completion of this transaction, the target company will become a wholly-owned subsidiary of the company, and a certain amount of goodwill is expected to be generated in the company's consolidated balance sheet. After this transaction, the company will fully integrate with the target company to ensure the target company's market competitiveness and long-term stable development capabilities. However, if there are adverse changes in the target company's future operating activities, the goodwill will be at risk of impairment and will have an adverse impact on the company's future current profit and loss.
Dai Lizhong, Chairman of Shengxiang Bio, said that efficient integration and personalization of prevention, diagnosis and treatment is the inevitable trend of proactive health, and is also the direction of Shengxiang Bio's innovation and exploration in the new era of life science.
The strong alliance between Shengxiang Bio and Zhongshan Haiji will leverage the resource advantages of precision diagnosis and biomanufacturing, which will help create an integrated health solution for pediatric diagnosis and treatment.
This acquisition has a certain premium. As of the valuation base date of May 31, 2024, the book value of all shareholders' equity of Zhongshan Haiji was RMB 259 million, the valuation was RMB 810 million, the appreciation was RMB 551 million, and the appreciation rate was 212.64%.
On the evening of January 12, announcement that it had updated the financial data of Zhongshan Haiji.
The company also pointed out the risks. Since the equity job seekers data acquisition is a merger of companies under different control, after the completion of this transaction, the target company will become a wholly-owned subsidiary of the company, and a certain amount of goodwill is expected to be generated in the company's consolidated balance sheet. After this transaction, the company will fully integrate with the target company to ensure the target company's market competitiveness and long-term stable development capabilities. However, if there are adverse changes in the target company's future operating activities, the goodwill will be at risk of impairment and will have an adverse impact on the company's future current profit and loss.
Dai Lizhong, Chairman of Shengxiang Bio, said that efficient integration and personalization of prevention, diagnosis and treatment is the inevitable trend of proactive health, and is also the direction of Shengxiang Bio's innovation and exploration in the new era of life science.
The strong alliance between Shengxiang Bio and Zhongshan Haiji will leverage the resource advantages of precision diagnosis and biomanufacturing, which will help create an integrated health solution for pediatric diagnosis and treatment.